Treatment | 293-R1α | 293-R1β | ||
---|---|---|---|---|
EC50 | Maximum AC Stimulation (100 nM CRH) | EC50 | Maximal AC Stimulation (100 nM CRH) | |
nM | % forskolin | nM | % forskolin | |
Control cells | ||||
+ CRH | 3 ± 2.2 | 61 ± 12.3 | 19 ± 5.0 | 15 ± 1.3 |
+ PMA/ | 4.8 ± 0.2 | 145 ± 21.4* | 30 ± 4.7 | 4 ± 1.3* |
CRH | ||||
+ IndoV/ | 6 ± 1.2 | 132 ± 32.3* | 23 ± 6.8 | 4.7 ± 1.6* |
CRH | ||||
H89-treated cells | ||||
+ CRH | 4 ± 0.2 | 57 ± 7.6 | 14 ± 2.2 | 13 ± 2.1 |
+ PMA/ | 3.1 ± 1.5 | 146 ± 12.1* | 25 ± 6.0 | 3.7 ± 0.6* |
CRH | ||||
+ indoV/ | 3.8 ± 0.9 | 139 ± 25.1* | 22 ± 2.5 | 4.2 ± 0.7* |
CRH | ||||
Calphostin C-treated cells | ||||
+ CRH | 5 ± 1.2 | 50 ± 8.9 | 17 ± 3.2 | 11 ± 1.0 |
+ PMA/ | 4 ± 0.2 | 65 ± 12.9 | 19 ± 2.4 | 8.5 ± 2.4 |
CRH | ||||
+ indoV/ | 4.7 ± 0.8 | 59 ± 7.2 | 23 ± 1.4 | 9.5 ± 2.1 |
CRH | ||||
Bisindolymaleimide I-treated cells | ||||
+ CRH | 3.2 ± 1.4 | 53 ± 9.9 | 13 ± 2.2 | 14 ± 3.2 |
+ PMA/ | 6 ± 0.7 | 55 ± 7.6 | 15 ± 4.5 | 9 ± 1.1 |
CRH | ||||
+ indoV/ | 6.5 ± 0.8 | 60 ± 5.9 | 16 ± 2.6 | 9.5 ± 2.4 |
CRH |
↵* p < 0.05 compared with cAMP response of cells without any pretreatment.